Singapore markets close in 7 hours 50 minutes
  • Straits Times Index

    3,134.87
    0.00 (0.00%)
     
  • Nikkei

    26,671.10
    -133.50 (-0.50%)
     
  • Hang Seng

    21,996.89
    -422.08 (-1.88%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • BTC-USD

    20,063.38
    -183.03 (-0.90%)
     
  • CMC Crypto 200

    431.36
    -8.31 (-1.89%)
     
  • S&P 500

    3,818.83
    -2.72 (-0.07%)
     
  • Dow

    31,029.31
    +82.32 (+0.27%)
     
  • Nasdaq

    11,177.89
    -3.65 (-0.03%)
     
  • Gold

    1,820.40
    +2.90 (+0.16%)
     
  • Crude Oil

    109.25
    -0.53 (-0.48%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • FTSE Bursa Malaysia

    1,451.48
    -3.26 (-0.22%)
     
  • Jakarta Composite Index

    6,942.35
    -54.10 (-0.77%)
     
  • PSE Index

    6,303.19
    -42.22 (-0.67%)
     

Why This FDA Approval Is a Game Changer for Eli Lilly

·3-min read
Why This FDA Approval Is a Game Changer for Eli Lilly
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting